Storite en es it fr

Storite Brand names, Storite Analogs

Storite Brand Names Mixture

  • No information avaliable

Storite Chemical_Formula


Storite RX_link

Storite fda sheet

Storite msds (material safety sheet)

Storite Synthesis Reference

No information avaliable

Storite Molecular Weight

192.258 g/mol

Storite Melting Point

246-266 oC

Storite H2O Solubility

1.07E+004 mg/L

Storite State


Storite LogP


Storite Dosage Forms

400 mg and 600 mg tablets for oral administration

Storite Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Storite Pharmacology

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.

Storite Absorption

Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.

Storite side effects and Toxicity

The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.

Storite Patient Information

Storite Organisms Affected

Humans and other mammals